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Abstract Rosacea is a chronic inflammatory disease that
can manifest as a spectrum of symptoms including ery-
thema, inflammatory lesions, edema, and telangiectasia.
Treatment decisions need to be adapted to reflect the nature
and severity of the different symptoms present. In this
report, we discuss the case of a female patient diagnosed
with severe, inflamed papulopustular rosacea (PPR) pre-
senting with a large number of inflammatory lesions and
severe background erythema. This patient responded well
to a treatment regimen consisting of a short course of
antibiotics in combination with a corticosteroid, followed
by monotherapy with isotretinoin to reduce the inflamma-
tion. Brimonidine gel, used as needed, was then added to
isotretinoin to target the remaining background erythema.
This case of severe PPR required a combinatorial treatment
regimen to effectively target all symptoms present. The
patient continued to apply topical metronidazole through-
out the different treatment regimens prescribed over the
course of almost 1 year. Use of topical metronidazole
helped to repair and protect the skin barrier, which mini-
mized the occurrence of dermatological adverse events
when topical treatments were used. We conclude that in
patients with severe disease and an important inflammatory
component, a rapid response can be obtained with a mul-
timodal, tailored approach that also includes treatment to
repair and protect the skin barrier.
Key Points
A patient with severe papulopustular rosacea (PPR)
and severe background erythema responded well to a
treatment regimen consisting of a short course of
antibiotics in combination with a corticosteroid,
followed by monotherapy with isotretinoin.
In patients with very severe, inflamed disease, it is
necessary to achieve a rapid response with a fast-
acting combinatorial treatment regimen to reduce the
inflammation.
Patients with severe PPR and an inflammatory
component can respond rapidly when treated using a
multimodal, tailored approach.
1 Background
Because rosacea presents as a spectrum of overlapping
symptoms of variable severity, it is important to adapt
treatment decisions to individual clinical presentations.
Papulopustular rosacea (PPR) is a commonly encountered
subtype of rosacea characterized by the presence of per-
sistent central facial erythema (background erythema),
accompanied by central facial inflammatory lesions
(papules and/or pustules) [1].
Patients with PPR often present with lesional and per-
ilesional erythema, which is found around and immediately
contiguous to a papule or pustule and contributes to the
overall appearance of facial redness [2]. Agents currently
approved for the treatment of the inflammatory lesions of
rosacea are known in clinical practice for their additional
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effect of decreasing the overall severity of facial erythema,
as a result of the reduction of the lesional and perilesional
erythema. However, these agents are not indicated in the
treatment of background erythema, which typically persists
after clearance of the inflammatory lesions [2].
Alternative treatments for the symptoms present in
patients with PPR include short courses of second-gener-
ation macrolides such as clarithromycin and azithromycin,
which have demonstrated a fast onset of action and a good
safety profile in the treatment of patients with PPR [3, 4].
These agents may therefore prove useful as an off-label
treatment in patients with severe disease who do not
respond to tetracycline therapy, or when isotretinoin is
contraindicated [5]. In addition, although corticosteroids
are not indicated for use in rosacea, their short-term use
may be considered in patients with severe disease who
present with signs of rosacea fulminans [6].
There is an increasing awareness of the need to repair
and protect the skin barrier as part of the treatment strategy
when prescribing treatments aimed at strongly targeting the
inflammatory component. It is known that an impaired skin
barrier leads to a heightened and potentially chronic
inflammatory response. Repairing and protecting the skin
barrier will decrease the risk of this process occurring,
while also reducing the incidence of dermatological
adverse events [7, 8].
Here, we report a case of severe PPR with an important
inflammatory component. A strategy aimed at strongly
targeting the inflammation upfront was successfully
implemented before addressing the remaining background
erythema component.
2 Case Description
In May 2014, a 30-year-old Caucasian woman presented to
our department (Fig. 1a). For the past 4 years, the patient
had suffered from severe PPR (principally on the forehead,
cheeks, and chin) with signs of rosacea fulminans, as well
as severe background erythema in the central facial and
forehead regions. She had previously been treated with
metronidazole 7.5 mg/g cream and permethrin 50 mg/g
cream, which had not provided a reduction in the number
of inflammatory lesions. She had also been prescribed
doxycycline modified-release 40 mg for 18 months, which
had also proved unsuccessful in reducing the inflammation.
At presentation, the patient reported feelings of hope-
lessness, indicating a profound impact of the disease on her
quality of life. Following diagnosis of PPR with severe
background erythema, different treatment options were
evaluated. In such a severe case, a specific strategy tailored
to the patient was essential, particularly given the lack of
success with prior regimens, which seemed to indicate that
a more potent treatment regimen was needed in this patient
to combat the inflammation upfront. Isotretinoin was ini-
tially considered; however, because the patient was not
taking hormonal contraception at the time of her visit to
our department, this therapy was contraindicated. The
patient was offered a gynecology appointment to start
hormonal contraception, so that isotretinoin could be an
option in the future. The patient was initially prescribed an
8-week regimen of azithromycin 500 mg three times
weekly (taken in the morning) in combination with pred-
nisolone 30 mg once daily (reduced to 10 mg once daily
after 1 week). The choice of this regimen was based on
results from the literature showing that a rapid response can
be obtained with a multimodal, tailored approach with a
short course of macrolide antibacterials [4]. Furthermore,
the use of corticosteroids over the short term is not strictly
contraindicated in the treatment of rosacea and can be
considered as an option to reduce inflammation in patients
who present with signs of rosacea fulminans [6]. Metron-
idazole 7.5 mg/g cream twice daily was continued with this
combination therapy.
After 4 weeks of treatment, a reduction in the inflam-
matory lesion count was observed (Fig. 1b). A slight
decrease in the severity of facial redness was also seen,
especially on the forehead, most likely resulting from a
reduction in lesional and perilesional erythema. The patient
continued to take azithromycin 500 mg three times weekly
and the prednisolone dose was reduced to 5 mg once daily.
In addition, the patient continued to apply metronidazole
7.5 mg/g cream twice daily.
During examination of the patient’s face 1 month later,
only a small number of inflammatory lesions were present
(Fig. 1c). The severity of erythema remained similar to that
observed during the previous visit, indicating a reduction in
the severity of the inflammation. Therapy with azi-
thromycin 500 mg three times weekly and prednisolone
5 mg once daily was stopped; treatment with isotretinoin
10 mg once daily (taken with the main meal) was initiated,
and application of metronidazole 7.5 mg/g cream twice
daily was continued.
When the patient returned to our department 4 months
later, no inflammatory lesions were present; however, the
erythema had worsened on the forehead and cheeks
(Fig. 1d). The patient continued to apply metronidazole
7.5 mg/g cream twice daily, as well as isotretinoin 10 mg
once daily for further improvement and as maintenance
therapy to prevent relapse of inflammatory lesions. Treat-
ment with brimonidine 3 mg/g gel, used as needed and
applied in the morning, was initially started to the left side
of her face in order to assess the impact of this agent on the
background erythema (split-face assessment). Brimonidine,
a highly selective a2-adrenergic receptor agonist [9], is
approved for the symptomatic treatment of facial erythema
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Fig. 1 Patient with rosacea presenting with overlapping symptoms of
severe inflammatory lesions and severe background erythema,
receiving sequential treatment with azithromycin 500 mg plus
prednisolone, isotretinoin 10 mg, and topical brimonidine 3 mg/g
gel; topical metronidazole 7.5 mg/g was administered throughout the
entire period. a May 2014 (baseline): patient with severe papulopus-
tular rosacea, with signs of rosacea fulminans, and severe background
erythema at initial presentation. b June 2014 (4 weeks after baseline):
4 weeks after initiation of treatment with azithromycin 500 mg three
times weekly plus once-daily prednisolone (30 mg for 1 week; 10 mg
for 3 weeks), in combination with metronidazole 7.5 mg/g cream
twice daily. c July 2014 (8 weeks after baseline): following a further
4 weeks of azithromycin 500 mg three times weekly, in combination
with once-daily prednisolone 5 mg treatment; the patient continued to
apply metronidazole 7.5 mg/g cream twice daily. Isotretinoin 10 mg
once daily was started. d October 2014 (25 weeks after baseline):
following 4 months of treatment with isotretinoin 10 mg once daily.
e December 2014 (32 weeks after baseline): following a further
2 months of treatment with isotretinoin 10 mg once daily in
combination with brimonidine 3 mg/g gel applied to the left side of
the face 3 h before presentation to our outpatient department. f March
2015 (43 weeks after baseline): following an additional 3 months.
Treatment with isotretinoin 10 mg once daily was stopped after
9 months; treatment with metronidazole 7.5 mg/g cream twice daily
was continued. The patient had applied brimonidine 3 mg/g gel to the
left side of her face on the morning of the visit to the clinic
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in adults with rosacea, in a formulation of brimonidine
3 mg/g gel (MIRVASO; Galderma International, La
De´fense, France) [10]. This agent has previously been
shown to be an effective option in the treatment of mod-
erate to severe erythema, with a good safety profile [9].
In December 2014, 2 months after commencing treat-
ment with brimonidine 3 mg/g gel on the left side of her
face and while continuing treatment with isotretinoin
10 mg once daily to maintain remission of inflammatory
lesions, the patient returned to our department, showing
mild erythema on the right side of the face, with back-
ground erythema cleared on the left side of the face
(Fig. 1e). Of note, during the treatment period with bri-
monidine 3 mg/g gel, the patient did not experience any
dermatological adverse events that required her to stop
treatment temporarily.
At the most recent visit to our department in March
2015, the patient showed an increase in erythema severity
on the right side of her face (not treated with brimonidine
3 mg/g gel) compared with the previous visit, reflecting the
dynamic and changing nature of this symptom. The left
side of the face, treated with brimonidine 3 mg/g gel on the
morning of the visit to the clinic, remained clear of ery-
thema (Fig. 1f). Isotretinoin treatment was stopped and the
patient was advised to continue maintenance therapy with
metronidazole 7.5 mg/g cream twice daily and brimonidine
3 mg/g gel.
3 Discussion and Evaluation
Here, we have reported the case of a patient with severe,
inflamed PPR with a high inflammatory lesion count and
severe erythema. Although corticosteroids are not gener-
ally recommended for the treatment of rosacea [6], because
the level of inflammation in this patient was high, and
similar to levels seen in patients with rosacea fulminans, it
was decided that the initial course of treatment should
consist of azithromycin 500 mg three times weekly in
combination with prednisolone (initially 30 mg once daily
and then gradually reduced and stopped). Following this
short course of treatment, the next step was to continue
decreasing the inflammation with isotretinoin 10 mg once
daily monotherapy, and finally isotretinoin 10 mg once
daily with brimonidine 3 mg/g gel on one side of the face
to address the background erythema component of the
disease.
In cases of recalcitrant PPR, oral isotretinoin can be
used over a 3- to 4-month treatment period to achieve a
complete clearance of inflammatory lesions [11]. In
selected cases, a longer duration of therapy may be
required in order to achieve an adequate level of
improvement [11]. In this case, following 4 months
treatment with isotretinoin, all inflammatory lesions had
disappeared. Treatment was continued for another
5 months to ensure maintained remission of inflammatory
lesions.
As the skin permeability barrier is often impaired in
rosacea, causing additional skin sensitivity and irritation
[8], metronidazole 7.5 mg/g cream twice daily was applied
throughout the courses of treatment, based on its proven
effects in reducing skin irritation, transepidermal water
loss, and erythema [12].
Based on the positive outcome seen overall, the patient
is currently on maintenance therapy with metronidazole
7.5 mg/g cream twice daily and brimonidine 3 mg/g gel,
with no relapse of disease.
4 Conclusions
In patients with very severe, inflamed rosacea, a multi-
modal, tailored approach with a short course of macrolide
antibiotics in combination with corticosteroids is needed to
strongly address the inflammatory component upfront and
improve patient outcomes; corticosteroids are not strictly
contraindicated in the treatment of rosacea if used for a
short period to reduce inflammation showing signs of
rosacea fulminans. In these patients, long-term therapy is
needed to improve outcomes, with isotretinoin being
effective in further reducing inflammatory lesions count
and in maintaining remission.
The patient experienced a continuous reduction in the
severity of her erythema, which was further improved with
the use of brimonidine 3 mg/g. The lack of reported der-
matological adverse events with this topical treatment
could in part be due to the continued application of
metronidazole; we believe metronidazole contributed to
repairing and protecting the skin barrier, helping to restore
skin barrier function and consequently lessening
inflammation.
For complex cases such as this one, it has been
acknowledged that careful selection and use of a combi-
nation of clinical treatments is essential to treat the indi-
vidual. However, appropriate treatment recommendations
and guidelines for such complex cases are still lacking. We
believe that the publication of additional multifaceted cases
such as the one presented here will help to facilitate the
development of such guidelines.
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